Icon to buy division of Cross Country Healthcare

February 4, 2013 by The Associated Press

Icon PLC plans to buy the clinical trial services division of Cross Country Healthcare Inc. in a deal potentially worth more than $55 million, as the Irish company seeks to grow globally and improve its drug safety consulting.

Icon, which is based in Dublin, said Monday it will pay $52 million in cash for the division plus an additional $3.75 million if some performance-based milestones are reached. It expects the deal to close within the next 30 days.

Icon provides development services to and medical device makers. Cross Country's clinical trial services division provides contract staffing and permanent placement services as well as work.

Cross Country, based in Boca Raton, Florida, said the clinical trial services business has been a "meaningful contributor" to the company for more than a decade. The company said it decided to sell it as part of a move to narrow its focus and focus on its resources on its and physician staffing businesses.

Cross Country Healthcare shares finished at $5.60 on Friday. That is nearer their 52-week high of $6.72 set last February. Its shares hit a low of $3.80 on mid-November.

Explore further: Pfizer will buy NextWave Pharma for up to $700M

shares

Related Stories

Pfizer will buy NextWave Pharma for up to $700M

October 22, 2012
(AP)—Pfizer said Monday it will buy NextWave Pharmaceuticals Inc., a company that makes a liquid attention deficit hyperactivity disorder drug, in a deal worth as much as $700 million.

Recommended for you

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors

April 30, 2017
Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing ...

'bench to bedside to bench': Scientists call for closer basic-clinical collaborations

March 24, 2017
In the era of genome sequencing, it's time to update the old "bench-to-bedside" shorthand for how basic research discoveries inform clinical practice, researchers from The Jackson Laboratory (JAX), National Human Genome Research ...

The ethics of tracking athletes' biometric data

January 18, 2017
(Medical Xpress)—Whether it is a FitBit or a heart rate monitor, biometric technologies have become household devices. Professional sports leagues use some of the most technologically advanced biodata tracking systems to ...

Financial ties between researchers and drug industry linked to positive trial results

January 18, 2017
Financial ties between researchers and companies that make the drugs they are studying are independently associated with positive trial results, suggesting bias in the evidence base, concludes a study published by The BMJ ...

Best of Last Year – The top Medical Xpress articles of 2016

December 23, 2016
(Medical Xpress)—It was a big year for research involving overall health issues, starting with a team led by researchers at the UNC School of Medicine and the National Institutes of Health who unearthed more evidence that ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.